Department of Medical Microbiology and Infection Prevention, Experimental Parasitology. Meibergdreef 9, Amsterdam University Medical Centres, Academic Medical Centre at the University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands.
Amsterdam Institute for Infection and Immunity, Infectious Diseases Programme, Amsterdam, The Netherlands.
Malar J. 2023 Mar 17;22(1):98. doi: 10.1186/s12936-023-04496-4.
Point-of-care diagnosis of malaria is currently based on microscopy and rapid diagnostic tests. However, both techniques have their constraints, including poor sensitivity for low parasitaemias. Hence, more accurate diagnostic tests for field use and routine clinical settings are warranted. The miniature direct-on-blood PCR nucleic acid lateral flow immunoassay (mini-dbPCR-NALFIA) is an innovative, easy-to-use molecular assay for diagnosis of malaria in resource-limited settings. Unlike traditional molecular methods, mini-dbPCR-NALFIA does not require DNA extraction and makes use of a handheld, portable thermal cycler that can run on a solar-charged power pack. Result read-out is done using a rapid lateral flow strip enabling differentiation of Plasmodium falciparum and non-falciparum malaria infections. A laboratory evaluation was performed to assess the performance of the mini-dbPCR-NALFIA for diagnosis of pan-Plasmodium and P. falciparum infections in whole blood.
Diagnostic accuracy of the mini-dbPCR-NALFIA was determined by testing a set of Plasmodium-positive blood samples from returned travellers (n = 29), and Plasmodium-negative blood samples from travellers with suspected malaria (n = 23), the Dutch Blood Bank (n = 19) and intensive care patients at the Amsterdam University Medical Centers (n = 16). Alethia Malaria (LAMP) with microscopy for species differentiation were used as reference. Limit of detection for P. falciparum was determined by 23 measurements of a dilution series of a P. falciparum culture. A fixed sample set was tested three times by the same operator to evaluate the repeatability, and once by five different operators to assess the reproducibility.
Overall sensitivity and specificity of the mini-dbPCR-NALFIA were 96.6% (95% CI, 82.2%-99.9%) and 98.3% (95% CI, 90.8%-100%). Limit of detection for P. falciparum was 10 parasites per microlitre of blood. The repeatability of the assay was 93.7% (95% CI, 89.5%-97.8%) and reproducibility was 84.6% (95% CI, 79.5%-89.6%).
Mini-dbPCR-NALFIA is a sensitive, specific and robust method for molecular diagnosis of Plasmodium infections in whole blood and differentiation of P. falciparum. Incorporation of a miniature thermal cycler makes the assay well-adapted to resource-limited settings. A phase-3 field trial is currently being conducted to evaluate the potential implementation of this tool in different malaria transmission areas.
目前,疟疾的即时诊断基于显微镜检查和快速诊断检测。然而,这两种技术都存在局限性,包括对低寄生虫血症的敏感性差。因此,需要更准确的诊断检测方法,以满足现场和常规临床环境的需求。微型直接血 PCR 核酸侧向流动免疫测定(mini-dbPCR-NALFIA)是一种创新的、易于使用的分子检测方法,可用于资源有限环境中的疟疾诊断。与传统的分子方法不同,mini-dbPCR-NALFIA 不需要 DNA 提取,而是利用手持式便携式热循环仪,该热循环仪可以在太阳能充电包上运行。结果读取使用快速侧向流动条进行,从而能够区分间日疟原虫和非间日疟原虫感染。进行了实验室评估,以评估微型 dbPCR-NALFIA 对全血中泛疟原虫和恶性疟原虫感染的诊断性能。
通过测试一组来自返回旅行者的疟原虫阳性血液样本(n=29)、来自疑似疟疾旅行者的疟原虫阴性血液样本(n=23)、荷兰血液银行(n=19)和阿姆斯特丹大学医学中心的重症监护患者(n=16),来确定微型 dbPCR-NALFIA 的诊断准确性。使用 Alethia Malaria(LAMP)进行显微镜鉴定以确定物种差异。通过 23 次恶性疟原虫培养稀释系列测量确定恶性疟原虫的检测限。同一个操作者对一个固定的样本集进行了 3 次测试,以评估重复性,然后由 5 个不同的操作者进行了 1 次测试,以评估再现性。
微型 dbPCR-NALFIA 的总体敏感性和特异性分别为 96.6%(95%CI,82.2%-99.9%)和 98.3%(95%CI,90.8%-100%)。恶性疟原虫的检测限为每微升血液 10 个寄生虫。该检测方法的重复性为 93.7%(95%CI,89.5%-97.8%),再现性为 84.6%(95%CI,79.5%-89.6%)。
微型 dbPCR-NALFIA 是一种敏感、特异且可靠的方法,可用于全血中疟原虫感染的分子诊断和恶性疟原虫的区分。微型热循环仪的加入使该检测方法非常适合资源有限的环境。目前正在进行一项 3 期现场试验,以评估该工具在不同疟疾传播地区的潜在应用。